6.39
6.50%
0.39
시간 외 거래:
6.39
전일 마감가:
$6.00
열려 있는:
$5.84
하루 거래량:
1.48M
Relative Volume:
1.22
시가총액:
$943.03M
수익:
$170.28M
순이익/손실:
$-225.25M
주가수익비율:
-4.8045
EPS:
-1.33
순현금흐름:
$-167.02M
1주 성능:
+1.43%
1개월 성능:
+44.57%
6개월 성능:
+99.69%
1년 성능:
+34.81%
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
명칭
Adaptive Biotechnologies Corp
전화
206-659-0067
주소
1165 EASTLAKE AVE E, SEATTLE, WA
ADPT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
6.39 | 943.03M | 170.28M | -225.25M | -167.02M | -1.56 |
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-07-05 | 재개 | JP Morgan | Overweight |
2023-01-05 | 개시 | Scotiabank | Sector Outperform |
2022-12-21 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2022-08-25 | 개시 | Credit Suisse | Underperform |
2022-06-03 | 개시 | Piper Sandler | Neutral |
2022-02-16 | 재확인 | BTIG Research | Buy |
2022-02-16 | 재확인 | BofA Securities | Buy |
2022-02-16 | 재확인 | Goldman | Neutral |
2022-02-16 | 재확인 | JP Morgan | Overweight |
2021-10-15 | 재개 | Cowen | Outperform |
2021-03-03 | 다운그레이드 | Goldman | Buy → Neutral |
2020-10-08 | 재개 | BTIG Research | Buy |
2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
2020-06-03 | 개시 | Goldman | Buy |
2019-07-23 | 개시 | BTIG Research | Buy |
2019-07-22 | 개시 | BofA/Merrill | Buy |
2019-07-22 | 개시 | Cowen | Outperform |
2019-07-22 | 개시 | Goldman | Neutral |
2019-07-22 | 개시 | Guggenheim | Buy |
2019-07-22 | 개시 | William Blair | Outperform |
모두보기
Adaptive Biotechnologies Corp 주식(ADPT)의 최신 뉴스
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
ADPT stock touches 52-week high at $6.71 amid robust gains By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $6.71 amid robust gains - Investing.com
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Point72 Asset Management L.P. Makes New $2.54 Million Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Pier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions - Yahoo Finance
ADPT (Adaptive Biotechnologies) 10-Year Sortino Ratio : N/A (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) 1-Year Sortino Ratio : 1.18 (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Adaptive Biotechnologies (STU:1HM) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Matrix Capital Management Company LP Sells 10,922,590 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Earnings Yield (Joel Gre - GuruFocus.com
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Short Interest Down 8.5% in November - MarketBeat
Adaptive Biotechnologies (STU:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies (STU:1HM) EPS (Diluted) : €-1.23 (TTM As of Sep. 2024) - GuruFocus.com
Cerity Partners LLC Boosts Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Rubric Capital Management LP Raises Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Massachusetts Financial Services Co. MA Lowers Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga
Millrace Asset Group Inc. Takes $1.40 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey - Defense World
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares - Investing.com India
Head to Head Comparison: Adaptive Biotechnologies (NASDAQ:ADPT) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Adaptive Biotechnologies Corp: Is ADPT Stock Worth Buying? - Stocks Register
Short Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Declines By 5.5% - Defense World
William Blair Has Bullish Forecast for ADPT FY2024 Earnings - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Decrease in Short Interest - MarketBeat
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know - Yahoo Finance
Rubric Capital Management LP's Strategic Acquisition in Adaptive Biotechnologies Corp - GuruFocus.com
Matrix Capital Management Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 12.7% Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00 - MarketBeat
ADPT (Adaptive Biotechnologies) Cash From Other Investing A - GuruFocus.com
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Earnings call: Adaptive Biotechnologies posts robust MRD revenue growth - Investing.com
ARK Investment Management LLC Buys 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highl - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):